- Home
- CRBP vs ACOG Comparison
CRBP vs ACOG Comparison
Compare CRBP & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- ACOG
- Stock Information
- Founded
- CRBP 2009
- ACOG 2000
- Country
- CRBP United States
- ACOG Canada
- Employees
- CRBP N/A
- ACOG N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- ACOG
- Sector
- CRBP Health Care
- ACOG
- Exchange
- CRBP Nasdaq
- ACOG Nasdaq
- Market Cap
- CRBP 103.6M
- ACOG 91.6M
- IPO Year
- CRBP N/A
- ACOG N/A
- Fundamental
- Price
- CRBP $8.18
- ACOG $6.28
- Analyst Decision
- CRBP Strong Buy
- ACOG
- Analyst Count
- CRBP 8
- ACOG 0
- Target Price
- CRBP $61.38
- ACOG N/A
- AVG Volume (30 Days)
- CRBP 291.7K
- ACOG 101.6K
- Earning Date
- CRBP 03-11-2025
- ACOG 11-15-2024
- Dividend Yield
- CRBP N/A
- ACOG N/A
- EPS Growth
- CRBP N/A
- ACOG N/A
- EPS
- CRBP N/A
- ACOG N/A
- Revenue
- CRBP N/A
- ACOG N/A
- Revenue This Year
- CRBP N/A
- ACOG N/A
- Revenue Next Year
- CRBP N/A
- ACOG N/A
- P/E Ratio
- CRBP N/A
- ACOG N/A
- Revenue Growth
- CRBP N/A
- ACOG N/A
- 52 Week Low
- CRBP $7.64
- ACOG $4.66
- 52 Week High
- CRBP $61.90
- ACOG $7.00
- Technical
- Relative Strength Index (RSI)
- CRBP 35.10
- ACOG N/A
- Support Level
- CRBP $7.64
- ACOG N/A
- Resistance Level
- CRBP $9.51
- ACOG N/A
- Average True Range (ATR)
- CRBP 0.84
- ACOG 0.00
- MACD
- CRBP -0.05
- ACOG 0.00
- Stochastic Oscillator
- CRBP 13.71
- ACOG 0.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.